These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26623727)

  • 1. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.
    Sestak V; Stariat J; Cermanova J; Potuckova E; Chladek J; Roh J; Bures J; Jansova H; Prusa P; Sterba M; Micuda S; Simunek T; Kalinowski DS; Richardson DR; Kovarikova P
    Oncotarget; 2015 Dec; 6(40):42411-28. PubMed ID: 26623727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
    Quach P; Gutierrez E; Basha MT; Kalinowski DS; Sharpe PC; Lovejoy DB; Bernhardt PV; Jansson PJ; Richardson DR
    Mol Pharmacol; 2012 Jul; 82(1):105-14. PubMed ID: 22508546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells.
    Dharmasivam M; Azad MG; Afroz R; Richardson V; Jansson PJ; Richardson DR
    Biochim Biophys Acta Gen Subj; 2022 Aug; 1866(8):130152. PubMed ID: 35436509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.
    Guo ZL; Richardson DR; Kalinowski DS; Kovacevic Z; Tan-Un KC; Chan GC
    J Hematol Oncol; 2016 Sep; 9(1):98. PubMed ID: 27678372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry.
    Stariat J; Kovaříková P; Kučera R; Klimeš J; Kalinowski DS; Richardson DR; Ketola RA
    Anal Bioanal Chem; 2013 Feb; 405(5):1651-61. PubMed ID: 23180090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion.
    Lui GY; Kovacevic Z; V Menezes S; Kalinowski DS; Merlot AM; Sahni S; Richardson DR
    Mol Pharmacol; 2015; 87(3):543-60. PubMed ID: 25561562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.
    Seebacher NA; Richardson DR; Jansson PJ
    Cell Death Dis; 2016 Dec; 7(12):e2510. PubMed ID: 27906178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).
    Gutierrez EM; Seebacher NA; Arzuman L; Kovacevic Z; Lane DJ; Richardson V; Merlot AM; Lok H; Kalinowski DS; Sahni S; Jansson PJ; Richardson DR
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1665-81. PubMed ID: 27102538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.
    Krishan S; Richardson DR; Sahni S
    Biochim Biophys Acta; 2016 Dec; 1863(12):2916-2933. PubMed ID: 27639899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells.
    Merlot AM; Sahni S; Lane DJ; Fordham AM; Pantarat N; Hibbs DE; Richardson V; Doddareddy MR; Ong JA; Huang ML; Richardson DR; Kalinowski DS
    Oncotarget; 2015 Apr; 6(12):10374-98. PubMed ID: 25848850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials.
    Reimerová P; Stariat J; Bavlovič Piskáčková H; Jansová H; Roh J; Kalinowski DS; Macháček M; Šimůnek T; Richardson DR; Štěrbová-Kovaříková P
    Anal Bioanal Chem; 2019 Apr; 411(11):2383-2394. PubMed ID: 30820631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
    Jansson PJ; Yamagishi T; Arvind A; Seebacher N; Gutierrez E; Stacy A; Maleki S; Sharp D; Sahni S; Richardson DR
    J Biol Chem; 2015 Apr; 290(15):9588-603. PubMed ID: 25720491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.
    Lovejoy DB; Sharp DM; Seebacher N; Obeidy P; Prichard T; Stefani C; Basha MT; Sharpe PC; Jansson PJ; Kalinowski DS; Bernhardt PV; Richardson DR
    J Med Chem; 2012 Aug; 55(16):7230-44. PubMed ID: 22861499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism.
    Merlot AM; Pantarat N; Menezes SV; Sahni S; Richardson DR; Kalinowski DS
    Mol Pharmacol; 2013 Dec; 84(6):911-24. PubMed ID: 24085840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.
    Park KC; Geleta B; Leck LYW; Paluncic J; Chiang S; Jansson PJ; Kovacevic Z; Richardson DR
    J Biol Chem; 2020 Jan; 295(2):481-503. PubMed ID: 31744884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex forming competition and in-vitro toxicity studies on the applicability of di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT) as a metal chelator.
    Gaál A; Orgován G; Polgári Z; Réti A; Mihucz VG; Bősze S; Szoboszlai N; Streli C
    J Inorg Biochem; 2014 Jan; 130():52-8. PubMed ID: 24176919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats.
    Stariat J; Suprunová V; Roh J; Šesták V; Eisner T; Filipský T; Mladěnka P; Nobilis M; Šimůnek T; Klimeš J; Kalinowski DS; Richardson DR; Kovaříková P
    Biomed Chromatogr; 2014 May; 28(5):621-9. PubMed ID: 24254882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and in vitro assessment of an anti-tumor nano-formulation.
    Holley CK; Kang YJ; Kuo CF; Abidian MR; Majd S
    Colloids Surf B Biointerfaces; 2019 Dec; 184():110481. PubMed ID: 31539751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.
    Yu Y; Suryo Rahmanto Y; Richardson DR
    Br J Pharmacol; 2012 Jan; 165(1):148-66. PubMed ID: 21658021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.
    Gutierrez E; Richardson DR; Jansson PJ
    J Biol Chem; 2014 Nov; 289(48):33568-89. PubMed ID: 25301941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.